一项针对既往接受过治疗的晚期胃癌患者，比较每周或每3周剂量的纳米白蛋白结合型紫杉醇与每周剂量的聚氧乙烯蓖麻油基紫杉醇的随机III期试验（ABSOLUTE试验）。
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
作者信息
Koizumi Wasaburo, Morita Satoshi, Sakata Yuh
机构信息
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa
Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto-shi, Kyoto.
出版信息
Jpn J Clin Oncol. 2015 Mar;45(3):303-6. doi: 10.1093/jjco/hyu205. Epub 2014 Dec 16.
Abstract
Paclitaxel is an agent widely used in second-line chemotherapy for advanced gastric cancer. The aim of this trial is to evaluate the efficacy and safety of 3-weekly or weekly doses of nanoparticle albumin-bound-paclitaxel compared with weekly doses of Cremophor-based paclitaxel in patients with unresectable or recurrent gastric cancer refractory to first-line chemotherapy comprising fluoropyrimidines. A total of 730 patients will be enrolled from 72 institutions. The primary endpoint is the overall survival, and the secondary endpoints are progression-free survival, time to treatment failure, overall response rate, disease control rate, quality of life (by using the EQ-5D system) and safety.
摘要
紫杉醇是一种广泛用于晚期胃癌二线化疗的药物。本试验的目的是评估每3周或每周一次剂量的纳米白蛋白结合型紫杉醇与每周一次剂量的聚氧乙烯蓖麻油基紫杉醇相比，在一线含氟嘧啶化疗难治的不可切除或复发性胃癌患者中的疗效和安全性。将从72个机构招募总共730名患者。主要终点是总生存期，次要终点是无进展生存期、治疗失败时间、总缓解率、疾病控制率、生活质量（使用EQ-5D系统）和安全性。
相似文献
1
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
Jpn J Clin Oncol. 2015 Mar;45(3):303-6. doi: 10.1093/jjco/hyu205. Epub 2014 Dec 16.
2
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1.
3
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19.
4
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30.
5
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14.
6
A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
Anticancer Res. 2018 Dec;38(12):6911-6917. doi: 10.21873/anticanres.13068.
7
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7.
8
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
9
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.
10
Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Int J Clin Oncol. 2020 Oct;25(10):1793-1799. doi: 10.1007/s10147-020-01724-8. Epub 2020 Jun 21.
引用本文的文献
1
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Invest New Drugs. 2024 Apr;42(2):171-178. doi: 10.1007/s10637-024-01425-3. Epub 2024 Feb 12.
2
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.
BMC Pharmacol Toxicol. 2023 Mar 1;24(1):13. doi: 10.1186/s40360-023-00653-2.
3
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Invest New Drugs. 2023 Feb;41(1):115-121. doi: 10.1007/s10637-023-01327-w. Epub 2023 Jan 12.
4
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma.
Mol Clin Oncol. 2022 Apr;16(4):87. doi: 10.3892/mco.2022.2520. Epub 2022 Feb 21.
5
Long-term response on letrozole for gastric cancer: A case report.
Medicine (Baltimore). 2021 May 28;100(21):e26146. doi: 10.1097/MD.0000000000026146.
6
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Sci Rep. 2017 Sep 7;7(1):10760. doi: 10.1038/s41598-017-11404-9.
7
Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.
Intern Med. 2017;56(8):921-923. doi: 10.2169/internalmedicine.56.7783. Epub 2017 Apr 15.
8
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Gastric Cancer. 2017 Mar;20(2):350-357. doi: 10.1007/s10120-016-0614-4. Epub 2016 May 17.
9
Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report.
Mol Clin Oncol. 2016 May;4(5):824-826. doi: 10.3892/mco.2016.782. Epub 2016 Feb 16.
10
Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.
Mol Clin Oncol. 2016 May;4(5):715-718. doi: 10.3892/mco.2016.803. Epub 2016 Mar 7.
本文引用的文献
1
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Gastric Cancer. 2016 Jul;19(3):902-10. doi: 10.1007/s10120-015-0542-8. Epub 2015 Sep 19.
2
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
3
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.
4
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4.
5
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
J Clin Oncol. 2012 May 1;30(13):1513-8. doi: 10.1200/JCO.2011.39.4585. Epub 2012 Mar 12.
6
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Eur J Cancer. 2011 Oct;47(15):2306-14. doi: 10.1016/j.ejca.2011.06.002.
7
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 2009 Nov;10(11):1063-9. doi: 10.1016/S1470-2045(09)70259-1. Epub 2009 Oct 7.
8
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20.
9
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Gastric Cancer. 2006;9(1):14-8. doi: 10.1007/s10120-005-0351-6.
10
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148.
Zotero 插件